Olaparib has been the first PARP inhibitor with reported positive results from a phase III trial in metastatic HER2-negative BC with germline BRCA1/2-mutation (see ClinicalTrials.gov Identifier: NCT02000622) [66,67]. This evidence concerns the gene ERBB2 and breast cancer.